Cisen Pharmaceutical Co., Ltd. (SHA:603367)

Cisen Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	4,244	4,451	4,049	3,773	3,666	3,950
Other Revenue	11.14	11.14	16.83	9.62	8.28	162.65
Revenue	4,255	4,462	4,066	3,783	3,674	4,113
Revenue Growth (YoY)	-2.51%	9.74%	7.50%	2.95%	-10.66%	8.00%
Cost of Revenue	1,819	1,913	1,827	1,728	1,610	1,792
Gross Profit	2,435	2,550	2,239	2,055	2,064	2,321
Selling, General & Admin	1,494	1,600	1,544	1,455	1,355	1,482
Research & Development	391.77	374.88	335.17	334.35	309.58	310.56
Other Operating Expenses	70.98	59.38	55.37	50.31	45.07	55.56
Operating Expenses	1,962	2,037	1,948	1,841	1,706	1,856
Operating Income	473.47	512.39	291.2	214.24	357.94	465.27
Interest Expense	-7.34	-6.59	-4.29	-6.1	-9.8	-0.26
Interest & Investment Income	79.74	85.7	53	90.18	83.09	56.78
Currency Exchange Gain (Loss)	0.55	0.55	-0.32	-0.62	-1.6	1.48
Other Non Operating Income (Expenses)	0.74	-1.27	-0.17	5.21	-3.55	-5.06
EBT Excluding Unusual Items	547.15	590.78	339.41	302.91	426.09	518.2
Gain (Loss) on Sale of Investments	5.64	-10.37	-3.12	-6.09	23.03	23.26
Gain (Loss) on Sale of Assets	0.04	0.59	0.97	0.27	0.17	0.44
Asset Writedown	-27.77	-27.79	0.01	-0.04	-1.05	-0.32
Other Unusual Items	87.63	42.65	28.92	39.09	36.28	40.53
Pretax Income	612.69	595.86	366.19	336.13	484.52	582.11
Income Tax Expense	79.5	70.43	13.92	2.23	47.16	67.32
Earnings From Continuing Operations	533.19	525.43	352.27	333.9	437.36	514.79
Minority Interest in Earnings	-4.18	-4.09	-2.31	0.24	1.42	-0.21
Net Income	529.01	521.34	349.96	334.15	438.78	514.58
Net Income to Common	529.01	521.34	349.96	334.15	438.78	514.58
Net Income Growth	18.06%	48.97%	4.73%	-23.85%	-14.73%	2.19%
Shares Outstanding (Basic)	452	453	454	452	452	451
Shares Outstanding (Diluted)	452	453	454	452	452	451
Shares Change (YoY)	-0.06%	-0.25%	0.65%	-0.18%	0.21%	-0.50%
EPS (Basic)	1.17	1.15	0.77	0.74	0.97	1.14
EPS (Diluted)	1.17	1.15	0.77	0.74	0.97	1.14
EPS Growth	18.14%	49.35%	4.05%	-23.71%	-14.91%	2.70%
Free Cash Flow	366.5	433.53	223.15	182.58	228.74	77.89
Free Cash Flow Per Share	0.81	0.96	0.49	0.40	0.51	0.17
Dividend Per Share	0.656	0.436	0.335	0.300	0.256	0.268
Dividend Growth	95.82%	30.15%	11.67%	17.19%	-4.48%	2.29%
Gross Margin	57.24%	57.14%	55.06%	54.32%	56.17%	56.43%
Operating Margin	11.13%	11.48%	7.16%	5.66%	9.74%	11.31%
Profit Margin	12.43%	11.68%	8.61%	8.83%	11.94%	12.51%
Free Cash Flow Margin	8.61%	9.71%	5.49%	4.83%	6.23%	1.89%
EBITDA	698.78	739.09	519.77	432.08	517.92	629.75
EBITDA Margin	16.42%	16.56%	12.78%	11.42%	14.10%	15.31%
D&A For EBITDA	225.31	226.71	228.57	217.84	159.98	164.48
EBIT	473.47	512.39	291.2	214.24	357.94	465.27
EBIT Margin	11.13%	11.48%	7.16%	5.66%	9.74%	11.31%
Effective Tax Rate	12.97%	11.82%	3.80%	0.66%	9.73%	11.56%
Revenue as Reported	4,255	4,462	4,066	3,783	3,674	4,113
Advertising Expenses	-	0.82	0.2	0.51	2.83	19.94

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.